Myriad Receives Reimbursement Decision For MyChoice Diagnost

Myriad Receives Reimbursement Decision For MyChoice Diagnostic System
TOKYO (dpa-AFX) - Myriad Genetics, Inc. (MYGN) said it received first reimbursement decision for the myChoice Diagnostic System, which helps determine if women with ovarian cancer will benefit from the PARP inhibitor, Zejula. myChoice was approved by Japan's Ministry of Health, Labour and Welfare in September 2020 as a companion diagnostic for this indication.
Myriad has been collaborating with Takeda Pharma in Japan since 2017 on the development of companion diagnostics. The company has partnered with SRL Inc. to commercialize the myChoice Diagnostic System in Japan.
Copyright RTT News/dpa-AFX
© 2021 AFX News

Related Keywords

Japan , Tokyo , Takeda Pharma , Genetics Inc , Japan Ministry Of Health , Choice Diagnostic System , Myriad , Receives , Reimbursement , Decision , Mychoice , Diagnostic , System , ஜப்பான் , டோக்கியோ , டாகேடா பார்மா , ஜெநெடிக்ஸ் இன்க் , ஜப்பான் அமைச்சகம் ஆஃப் ஆரோக்கியம் , தேர்வு கண்டறியும் அமைப்பு , எண்ணற்ற , கொடுக்கப்படுவதுடன் , முடிவு , கண்டறியும் , அமைப்பு ,